Novo Nordisk, fighting competition to its blockbuster Victoza, just posted data on a follow-up drug that gives it an edge over archrival Trulicity. That Lilly med has stolen share from Victoza, but the new head-to-head results, coupled with CV...
For almost a century, pharmaceutical giant Novo Nordisk rolled out new versions of its core product at higher prices. Then suddenly, governments and insurers decided the older, less expensive versions were good enough.
Novo Nordisk CEO Lars Fruergaard Jorgensen knows that his company is facing pressure in the US over the rising price of the diabetes medication insulin.
Jorgensen told Business Insider that he expects that people who have trouble paying for...
Novo Nordisk, like its rival drugmakers in diabetes, is still grappling with the pricing pressure that’s assaulted the business for a couple of years. That’s the bad news. The good? Pricing isn’t the be-all of growth. It’s portfolio.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Novo Nordisk A/S (NVO):